Step-down and move forward
- PMID: 32383822
- DOI: 10.1002/pbc.28342
Step-down and move forward
Comment on
-
Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.Pediatr Blood Cancer. 2020 Jun;67(6):e28251. doi: 10.1002/pbc.28251. Epub 2020 Mar 20. Pediatr Blood Cancer. 2020. PMID: 32196898 Clinical Trial.
References
REFERENCES
-
- Aviles-Robles MJ, Reyes-Lopez A, Otero-Mendoza FJ, et al. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: a noninferiority multicenter randomized clinical trial. Pediatr Blood Cancer. 2020:e28251. https://doi.org/10.1002/pbc.28251. Accessed April 25, 2020.
-
- Teuffel O, Sung L. Advances in management of low-risk febrile neutropenia. Curr Opin Pediatr. 2012;24(1):40-45.
-
- Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013;57(6):781-788.
-
- Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis. 2017;17(1):404.
-
- Han SB, Jung SW, Bae EY, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children. Microb Drug Resist. 2015;21(2):244-251.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
